The Food and Drug Administration (FDA) is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act amends and updates the Pediatric Research Equity Act (PREA). RACE Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology. This paper discusses the need for and the importance of pediatric research, the RACE Act, and how it applies to precision medicine.
The Center for Pediatric Clinical Development
We’re driving pediatric clinical research forward and protecting kids through research, not from it.
The RACE for Children Act
In the US, legislation such as the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) have helped to…
PRA's highly specialized, patient-focused experts bring innovation to pediatric clinical design, ensuring safe, pediatric-tested treatments for…